A single gene called FOXJ3 controls brain layering and, when broken, causes drug-resistant epilepsy

It started with one family. A Taiwanese family with drug-resistant epilepsy and focal cortical dysplasia (FCD) walked into the epilepsy division at Taipei Veterans General Hospital, and Dr. Yo-Tsen Liu ran the genetic tests. What came back was a mutation in a gene called FOXJ3, a transcription factor that had not previously been linked to epilepsy. That finding launched a multinational investigation that now connects a single gene to one of the most treatment-resistant forms of the disease.

The results, published in Nature Communications, come from a collaboration between National Yang Ming Chiao Tung University (NYCU) in Taiwan, University College London, and partners in Belgium.

How the brain builds its layers

The cerebral cortex has six distinct layers, assembled during fetal development in a precise inside-out sequence. Neurons are born deep in the brain, then migrate outward, each new wave passing through the previous ones to take its position in the correct layer. This process requires tight coordination between cell division, migration, and differentiation.

FOXJ3, the researchers found, is highly active in neural progenitor cells during the early stages of cortex formation. It acts as a transcriptional regulator, turning on the gene for PTEN, a well-known tumor suppressor that also keeps the mTOR signaling pathway in check. PTEN restrains mTOR, and mTOR drives cell growth, proliferation, and survival.

When FOXJ3 carries a disease-associated mutation, it fails to activate PTEN. Without that brake, mTOR signaling runs unchecked. Neurons grow too large, adopt abnormal shapes, and end up in the wrong cortical layer. The result is focal cortical dysplasia, a structural brain malformation that is the single most common cause of epilepsy that does not respond to medication.

Rescuing the defect in experimental models

The research team did not stop at identifying the mechanism. They tested whether restoring PTEN activity could reverse the cortical defects caused by FOXJ3 mutations. In mouse models and single-cell analyses, re-introducing functional PTEN was sufficient to rescue the cortical layering defects. Neurons migrated correctly and assumed their proper positions.

This is significant because the mTOR pathway is already a therapeutic target. Drugs that inhibit mTOR, such as everolimus, are used to treat other mTOR-related conditions including tuberous sclerosis complex. The identification of a FOXJ3-PTEN-mTOR axis in focal cortical dysplasia opens the possibility of using existing mTOR inhibitors or developing more targeted therapies for patients with FOXJ3 mutations.

A diagnosis that changes families

Dr. Sanjay Sisodiya of UCL Queen Square Institute of Neurology, a co-author, notes that discovering the specific genetic cause of a patient's epilepsy carries weight beyond the laboratory. For the individual and their family, it can end years of diagnostic uncertainty, inform genetic counseling and family planning, and open the door to rational treatment selection rather than trial-and-error prescribing.

FCD type II, the form most associated with drug-resistant epilepsy, often presents with normal-appearing brain MRI scans, making diagnosis particularly challenging. Genetic testing for FOXJ3 variants could improve diagnostic yield in these patients, especially when conventional imaging fails to reveal a structural abnormality.

Cross-continent, cross-ethnicity validation

The study drew on patient genetics from both Taiwanese and British populations, with support from Genomics England and the UCL Institute of Neurology. This cross-ethnic validation matters. Many genetic findings in epilepsy have been identified in populations of European descent, and demonstrating that FOXJ3 mutations cause disease across different ethnic backgrounds strengthens the case for its clinical relevance globally.

Scale of the problem

Epilepsy affects more than 50 million people worldwide, and a substantial proportion do not respond to existing medications. For these patients, understanding the developmental and genetic roots of their condition is not an academic exercise. It is the prerequisite for any treatment that addresses cause rather than symptom.

The study adds FOXJ3 to the growing list of genes implicated in mTOR pathway disorders, collectively known as mTORpathies. But its particular contribution is mechanistic clarity: it traces a path from a single transcription factor through a specific tumor suppressor to a well-characterized signaling cascade, and it shows that intervening at the right point in that cascade can correct the downstream damage. That kind of precision is what makes a genetic discovery actionable.